News Home

Analyst Rating: Will Fate Therapeutics Inc (FATE) Stock Lead the Market?

Wednesday, November 17, 2021 02:29 PM | InvestorsObserver Analysts
Analyst Rating: Will Fate Therapeutics Inc (FATE) Stock Lead the Market?

Wall Street is positive on Fate Therapeutics Inc (FATE). On average, analysts give the stock a Strong Buy rating. The average price target is $107.533, which means analysts expect the stock to climb by 100.92% over the next twelve months. That average ranking earns the stock an Analyst Rating of 59, which is better than 59% of stocks based on data compiled by InvestorsObserver.

Overall Score - 4.6
Wall Street analysts are rating FATE a Strong Buy today. Find out what this means to you and get the rest of the rankings on FATE!

Why are Analyst Ratings Important?

Analytical research by professionals can be extremely useful when making investment decisions in the stock market. Analysts are able to observe industries in detail and learn how geographical impacts can affect a company's balance sheet. This information allows investors to make decisions ahead of the curve. InvestorsObserver combines the ratings from these analysts and proceeds to percentile rank them. This grants you the ability to compare stocks in a comprehensive fashion as oppossed to a standard buy/hold/sell rating.

What's Happening With Fate Therapeutics Inc Stock Today?

Fate Therapeutics Inc (FATE) stock is trading at $53.52 as of 2:25 PM on Wednesday, Nov 17, a loss of -$1.97, or -3.55% from the previous closing price of $55.49. The stock has traded between $52.58 and $55.78 so far today. Volume today is less active than usual. So far 458,300 shares have traded compared to average volume of 874,491 shares. Click Here to get the full Stock Report for Fate Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App